Thus, in patients with prostate cancer harboring ARNEG tumor cells or treated with androgen-deprivation therapy/ARIs, and with the IL1β gene unmethylated, IL1β could condition the metastatic microenvironment to sustain disease progression. The gene discussed is IL1B; the disease is prostate carcinoma.